| Obesity
Xenical vs Wegovy
Side-by-side clinical, coverage, and cost comparison for obesity.Deep comparison between: Xenical vs Wegovy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsWegovy has a higher rate of injection site reactions vs Xenical based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Wegovy but not Xenical, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xenical
Wegovy
At A Glance
Oral
Three times daily
Gastrointestinal lipase inhibitor
SC injection
Once weekly
GLP-1 receptor agonist
Indications
- Obesity
- Obesity
- Nonalcoholic Steatohepatitis
Dosing
Obesity One 120-mg capsule three times a day with each main meal containing fat (during or up to 1 hour after the meal); distribute daily fat, carbohydrate, and protein over three main meals.
Obesity Adults: maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg; pediatric patients aged 12 years and older: 2.4 mg (or 1.7 mg) SC injection once weekly.
Nonalcoholic Steatohepatitis 2.4 mg SC injection once weekly (maintenance) after escalation from 0.25 mg; may reduce to 1.7 mg once weekly if 2.4 mg not tolerated.
Cardiovascular risk reduction Maintenance 2.4 mg (or 1.7 mg) SC injection once weekly after escalation from 0.25 mg, or 25 mg tablet orally once daily after escalation from 1.5 mg.
Contraindications
- Pregnancy
- Chronic malabsorption syndrome
- Cholestasis
- Known hypersensitivity to XENICAL or to any component of this product
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Prior serious hypersensitivity reaction to semaglutide or to any excipient in WEGOVY injection or WEGOVY tablet
Adverse Reactions
Most common (>=5%) Oily spotting, flatus with discharge, fecal urgency, fatty/oily stool, oily evacuation, increased defecation, fecal incontinence
Postmarketing Hepatitis, hepatic failure, hypersensitivity reactions (pruritus, rash, urticaria, angioedema, bronchospasm, anaphylaxis), bullous eruption, leukocytoclastic vasculitis, acute oxalate nephropathy, pancreatitis, lower gastrointestinal bleeding
Most common (>=2%) Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, eructation, flatulence, gastroenteritis, gastroesophageal reflux disease, gastritis, hair loss, dysesthesia
Serious Risk of thyroid C-cell tumors, acute pancreatitis, acute gallbladder disease, hypoglycemia, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions including anaphylaxis and angioedema, diabetic retinopathy complications, heart rate increase, pulmonary aspiration during anesthesia
Postmarketing Acute pancreatitis and necrotizing pancreatitis, ileus, intestinal obstruction, severe constipation including fecal impaction, anaphylaxis, angioedema, rash, urticaria, pulmonary aspiration, acute kidney injury
Pharmacology
Orlistat is a reversible inhibitor of gastrointestinal lipases that forms a covalent bond with the active serine residue site of gastric and pancreatic lipases, preventing hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides, resulting in a caloric deficit that may have a positive effect on weight control.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1 that selectively binds and activates the GLP-1 receptor, regulating appetite and caloric intake, stimulating glucose-dependent insulin secretion, reducing glucagon secretion, and delaying gastric emptying.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xenical
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (4/12) · Qty limit (9/12)
Wegovy
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Xenical
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Wegovy
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
Xenical
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Wegovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xenical.
$349/momo
Wegovy Self-Pay Program - InjectableCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XenicalView full Xenical profile
WegovyView full Wegovy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.